Skip to main content

Advertisement

SpringerLink
Log in

Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients

  • Review Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

The elderly form a very heterogeneous group in relation to their general health state, degree of dependence, comorbidities, performance status, physical reserve and geriatric situation, so cancer treatment in the older patient remains a therapeutic challenge. The physiological changes associated with aging increase the risk of developing a serious toxicity induced by chemotherapy treatment, as well as other undesirable consequences as hospitalizations, dependence and non-compliance with treatment, that can negatively affect survival, quality of life and treatment efficacy. The use of hematopoietic growth factors and other active supportive interventions in the elderly can help prevent and/or alleviate these toxicities. However, we have little data on the efficacy and tolerance of support treatments in the older patient. The objective of this work is to review the most frequent toxicities of oncological treatments in the elderly and their management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gajta A, Klepin HD, Feng T, et al. Predictors chemotherapy dose reduction at first cycle in patients age 65 years and older with solid tumors. J Geriatr Oncol. 2015;6:133–40.

    Google Scholar 

  2. Feliu J, Heredia-Soto V, Gironés R, et al. Can we avoid the toxicity of chemotherapy in elderly cancer patients? Crit Rev Oncol Hematol. 2018;131:16–23.

    PubMed  Google Scholar 

  3. Asmis TR, Ding K, Seymour L, et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 2008;26:54–9.

    CAS  PubMed  Google Scholar 

  4. Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007;25:3699–704.

    CAS  PubMed  Google Scholar 

  5. Blanchard EM, Moon J, Hesketh PJ, et al. Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509. J Thorac Oncol. 2011;6:115–20.

    PubMed  PubMed Central  Google Scholar 

  6. Mohile SG, Hardt M, Tew W, et al. Toxicity of bevacizumab in combination with chemotherapy in older patients. Oncologist. 2013;18:408–14.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Kleipin HD, Rodin M, Hurria A. Treating adults with cancer: geariatric perspectives. ASCO Educ Book. 2015;e544–52.

  8. Creditor MC. Hazards of hospitalization of the elderly. Ann Intern Med. 1993;118:219–23.

    CAS  PubMed  Google Scholar 

  9. Sager MA, Franke T, Inouye SK, et al. Functional outcomes of acute medical illness and hospitalization in older persons. Arch Intern Med. 1996;156:645–52.

    CAS  PubMed  Google Scholar 

  10. Shahrokni A, Wu AJ, Carter J, Lichtman SM. Long-term toxicity of cancer treatment in older patients. Clin Geriatr Med. 2016;32:63–80.

    PubMed  Google Scholar 

  11. Ward PR, Wong MD, Moore R, Naeim A. Fall-related injuries in elderly cancer patients treated with neurotoxic chemotherapy: a retrospective cohort study. J Geriatr Oncol. 2014;5:57–64.

    PubMed  Google Scholar 

  12. Kelly CM, Power DG, Lichtman SM. Targeted therapy in older patients with solid tumors. J Clin Oncol. 2014;32:2635–46.

    CAS  PubMed  Google Scholar 

  13. Daste A, Chakiba C, Domblides C, et al. Targeted therapy and elderly people: a review. Eur J Cancer. 2016;69:199–21515.

    PubMed  Google Scholar 

  14. Nightingale G, Schwartz R, Kachur E, et al. Clinical pharmacology of oncology agents in older adults: a comprehensive review of how chronologic and functional age can influence treatment-related effects. J Geriatr Oncol. 2019;10:4–30.

    PubMed  Google Scholar 

  15. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20:494–502.

    PubMed  Google Scholar 

  16. Balducci L, Colloca G, Cesari M, et al. Assessment and treatment of elderly patients with cancer. Surg Oncol. 2010;19:117–23.

    PubMed  Google Scholar 

  17. Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology Consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32:2595–603.

    PubMed  PubMed Central  Google Scholar 

  18. Extermann M, Aapro M, Bernabei R, Cohen HJ, Droz JP, Lichtman S, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241–52.

    PubMed  Google Scholar 

  19. Luciani A, Biganzoli L, Colloca G, et al. Estimating the risk of chemotherapy toxicity in older patients with cancer: the role of the Vulnerable Elders Survey-13 (VES-13). J Geriatr Oncol. 2015;6:272–9.

    PubMed  Google Scholar 

  20. Decoster L, Van Puyvelde K, Mohile S, et al. Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations. Ann Oncol. 2015;26:288–300.

    CAS  PubMed  Google Scholar 

  21. Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29:3457–65.

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118:3377–86.

    PubMed  Google Scholar 

  23. Kim JW, Lee YG, Hwang IG, Song HS, Koh SJ, Ko YH, et al. Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. Br J Cancer. 2018;118:1169–75.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Aparicio T, Jouve JL, Teillet L, Gargot D, Subtil F, Le Brun-Ly V, et al. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001–2002 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol. 2013;31:1464–70.

    CAS  PubMed  Google Scholar 

  25. Freyer G, Geay JF, Touzet S, Provencal J, Weber B, Jacquin JP, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol. 2005;16:1795–800.

    CAS  PubMed  Google Scholar 

  26. Maione P, Perrone F, Gallo C, Manzione L, Piantedosi F, Barbera S, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol. 2005;23:6865–72.

    PubMed  Google Scholar 

  27. Hurria A, Mohile S, Gajra A, Klepin H, Muss H, Chapman A, et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol. 2016;34:2366–71.

    PubMed  PubMed Central  Google Scholar 

  28. Moth EB, Kiely BE, Stefanic N, Naganathan V, Martin A, Grimison P, et al. Predicting chemotherapy toxicity in older adults: comparing predictive value of the CARG Toxicity Score with oncologists’ estimates of toxicity based on clinical judgement. J Geriatr Oncol. 2018;18:30342–4.

    Google Scholar 

  29. Lichtman SM, Wildiers H, Chatelut E, et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients–an analysis of the medical literature. J Clin Oncol. 2007;25:1832–43.

    CAS  PubMed  Google Scholar 

  30. Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038–51.

    CAS  PubMed  Google Scholar 

  31. Balducci L, Repetto L. Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer. 2004;100:6–11.

    PubMed  Google Scholar 

  32. Chan A, Lee CP, Chiang J, Ng R. Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas. Support Care Cancer. 2013;21:2137–43.

    PubMed  Google Scholar 

  33. NCCN Guidelines for Myeloid Growth Factors. Version 1.2018. https://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf. Accessed 29 Jan 2018.

  34. Repetto L, Biganzoli L, Kohene CH, et al. EORTC Cancer in the elderly task force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer. 2003;39:2264–72.

    CAS  PubMed  Google Scholar 

  35. Repetto L. Greater risks of chemotherapy toxicity in elderly patients with cancer. J Support Oncol. 2003;1(4 Suppl 2):18–24.

    PubMed  Google Scholar 

  36. Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines Ann Oncol. 2016;27(Supplement 5):v111–v118.

    CAS  PubMed  Google Scholar 

  37. Aapro M, Bokemeyer C, Ludwig H, et al. Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: patterns, outcomes, and determinants (MONITOR-GCSF study). J Geriatr Oncol. 2017;8:86–95.

    PubMed  Google Scholar 

  38. Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353:988–98.

    CAS  PubMed  Google Scholar 

  39. Metivier F, Marchais SJ, Guerin AP, et al. Pathophysiology of anaemia: focus on the heart and blood vessels. Nephrol Dial Transplant. 2000;15(Suppl 3):14–8.

    PubMed  Google Scholar 

  40. NCCN Guidelines for cancer- and chemotherapy-induced anemia. Version 2.2018. https://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf. Accessed 14 Apr 2018.

  41. Hurria A, Dale W, Mooney M, et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014;32:2587–94.

    PubMed  PubMed Central  Google Scholar 

  42. Balducci L, Carreca I. The role of myelopoietic growth factors in managing cancer in the elderly. Drugs. 2002;62:47–63.

    CAS  PubMed  Google Scholar 

  43. Dicato M. Venous thromboembolic events and erythropoiesis-stimulating agents: an update. Oncologist. 2008;13(Suppl 3):11–5.

    CAS  PubMed  Google Scholar 

  44. Bian J, Chen B, Hershman DL, et al. Effects of the US Food and Drug Administration boxed warning of erythropoietin-stimulating agents on utilization and adverse outcome. J Clin Oncol. 2017;35:1945–51.

    PubMed  PubMed Central  Google Scholar 

  45. Bennett CL, Silver SM, Djubegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoetin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299:914–24.

    CAS  PubMed  Google Scholar 

  46. Bohlius J, Scmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373:1532–42.

    CAS  PubMed  Google Scholar 

  47. Chapell R, Aapro M. Efficacy of aprepitant among patients aged 65 and over receiving moderately to highly emetogenic chemotherapy: a meta-analysis of unpublished data from previously published studies. J Geriatr Oncol. 2013;4:78–83.

    PubMed  Google Scholar 

  48. Benson AB 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22:2918–26.

    CAS  PubMed  Google Scholar 

  49. NCCN Guidelines in Oncology. Older adult oncology. Version 1.2018. https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf. Accessed 29 Jan 2018.

  50. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120:1453–61.

    PubMed  PubMed Central  Google Scholar 

  51. Peterson DE, Boers-Doets CB, Bensadoun RJ, et al. Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2015;26(Suppl 5):v139–v151151.

    PubMed  Google Scholar 

  52. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590–8.

    CAS  PubMed  Google Scholar 

  53. Boehm S, Rothermundt C, Hess D, Joerger M. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly—a minireview. Gerontology. 2010;56:303–9.

    CAS  PubMed  Google Scholar 

  54. Pinder M, Duan Z, Goodwin J, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:3808–15.

    CAS  PubMed  Google Scholar 

  55. Aapro M, Bernard-Marty C, Brain EG, et al. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol. 2011;22:257–67.

    CAS  PubMed  Google Scholar 

  56. Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005;23:7685–96.

    CAS  PubMed  Google Scholar 

  57. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53:2231–47.

    CAS  PubMed  Google Scholar 

  58. Skillings JR, Johnson DH, Miller K, et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. J Clin Oncol. 2005;23:3019.

    Google Scholar 

  59. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007;99:1232–9.

    PubMed  Google Scholar 

  60. Peterson LL, Hurria A, Feng T, et al. Association between renal function and chemotherapy-related toxicity in older adults with cancer. J Geriatr Oncol. 2017;8:96–101.

    PubMed  Google Scholar 

  61. Koll T, Pergolotti M, Holmes HM, et al. Supportive care in older adults with cancer: across the continuum. Curr Oncol Rep. 2016;18:51.

    PubMed  PubMed Central  Google Scholar 

  62. Smith GA, Damon LE, Rugo HS, et al. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol. 1997;15:833–9.

    CAS  PubMed  Google Scholar 

  63. Wildes TM, Dua P, Fowler SA, et al. Systematic review of falls in older adults with cancer. J Geriatr Oncol. 2015;6:70–83.

    PubMed  Google Scholar 

  64. Tofthagen C, Overcash J, Kip K. Falls in persons with chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2012;20:583–9.

    PubMed  Google Scholar 

  65. Gewandter JS, Fan L, Magnuson A, et al. Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN) a University of Rochester CCOP study. Support Care Cancer. 2013;21:2059–66.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trials. JAMA. 2013;309:1359–67.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Balducci L, Dolan D, Hoffe SA. Palliative care in older patients with cancer. Cancer Control. 2015;22:480–8.

    PubMed  Google Scholar 

  68. Ciorba A, Bianchini C, Pelucchi S, et al. The impact of hearing loss on the quality of life of elderly adults. Clin Interv Aging. 2012;7:159–63.

    PubMed  PubMed Central  Google Scholar 

  69. Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int. 2007;18:1033–46.

    CAS  PubMed  Google Scholar 

  70. Shahinian VB, Kuo Y-F, Freeman JL, et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–64.

    CAS  PubMed  Google Scholar 

  71. Chen Z, Maricic M, Pettinger M, et al. Osteoporosis and rate of bone loss among postmenopausal survivors of breast cancer. Cancer. 2005;104:1520–30.

    PubMed  Google Scholar 

  72. Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med. 2012;367:40–9.

    CAS  PubMed  Google Scholar 

  73. Naeim A, Aapro M, Subbarao R, Balducci L. Supportive care considerations for older adults with cancer. J Clin Oncol. 2014;32:2627–34.

    PubMed  Google Scholar 

  74. Berntsen S, Aaronson NK, Buffart L, et al. Design of a randomized controlled trial of physical training and cancer (Phys-Can)—the impact of exercise intensity on cancer related fatigue, quality of life and disease outcome. BMC Cancer. 2017;17:218.

    PubMed  PubMed Central  Google Scholar 

  75. Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al. Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol. 2013;31:3076–82.

    CAS  PubMed  Google Scholar 

  76. Aapro M, Scotte F, Bouillet T, et al. A practical approach to fatigue management in colorectal cancer. Clin Colorectal Cancer. 2017;16:275–85.

    PubMed  Google Scholar 

  77. Barton DL, Liu H, Dakhil SR, et al. Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013;105:1230–8.

    PubMed  PubMed Central  Google Scholar 

  78. Yennurajalingam S, Tannir NM, Williams JL, et al. A double-blind, randomized, placebo-controlled trial of panax ginseng for cancer-related fatigue in patients with advanced cancer. J Natl Compr Cancer Netw. 2017;15:1111–20.

    Google Scholar 

  79. Corre R, Gervais R, Guisier F, et al. Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study). Oncotarget. 2018;9:8253–62.

    PubMed  PubMed Central  Google Scholar 

  80. Agostara B, Carruba G, Usset A. The management of cancer in the elderly: targeted therapies in oncology. Immun Ageing. 2008;5:16.

    PubMed  PubMed Central  Google Scholar 

  81. Gonsalves W, Ganti AK. Targeted anti-cancer therapy in the elderly. Crit Rev Oncol Hematol. 2011;78:227–42.

    PubMed  Google Scholar 

  82. Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15:436–44.

    CAS  PubMed  Google Scholar 

  83. Mohile SG, Xian Y, Dale W, et al. Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries. J Natl Cancer Inst. 2009;101:1206–15.

    PubMed  PubMed Central  Google Scholar 

  84. Wedding U, Pientka L, Hoffken K. Quality-of-life in elderly patients with cancer: a short review. Eur J Cancer. 2007;43:2203–10.

    PubMed  Google Scholar 

  85. Balducci L, Extermann M. Management of the frail person with advanced cancer. Crit Rev Oncol Hematol. 2000;33:143–8.

    CAS  PubMed  Google Scholar 

  86. Cazzaniga ME, Camerini A, Addeo R, et al. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development. Future Oncol. 2016;12:373–87.

    CAS  PubMed  Google Scholar 

  87. Hassett MJ, Rao SR, Brozovic S, et al. Chemotherapy-related hospitalization among community cancer center patients. Oncologist. 2011;16:378–87.

    PubMed  PubMed Central  Google Scholar 

  88. Hassett MJ, O'Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006;98:1108–17.

    PubMed  Google Scholar 

  89. Magai C, Consedine N, Neugut A, Hershman D. Common psychosocial factors underlying breast cancer screening and breast cancer treatment adherence: a conceptual review and synthesis. J Womens Health. 2007;16:11–23.

    Google Scholar 

  90. Atkins L, Fallowfield L. Intentional and nonintentional non-adherence to medication amongst breast cancer patients. Eur J Cancer. 2006;42:2271–6.

    PubMed  Google Scholar 

  91. Visram H, Kanji F, Dent SF. Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol. 2010;17:17–211.

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Maloney KW, Kagan SH. Adherence and oral agents with older patients. Semin Oncol Nurs. 2011;27:154–60.

    PubMed  Google Scholar 

  93. Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early stage breast cancer patients. J Clin Oncol. 2010;28:4120–8.

    PubMed  PubMed Central  Google Scholar 

  94. Owusu C, Buist DS, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008;26:549–55.

    PubMed  Google Scholar 

  95. Hershman DL, Shao T, Kushi LH, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126:529–37.

    CAS  PubMed  Google Scholar 

Download references

Funding

No funding was received.

Author information

Authors and Affiliations

  1. Medical Oncology Department, H. Universitario La Paz, CIBERONC, Paseo de la Castellana 261, 28046, Madrid, Spain

    J. Feliu & V. Heredia-Soto

  2. Medical Oncology Department, H. Lluís Alcanyís. Xàtiva, Valencia, Spain

    R. Gironés

  3. Medical Oncology Department, H. Universitario Clara Campal, Madrid, Spain

    B. Jiménez-Munarriz

  4. Medical Oncology Department, Instituto Catalán de Oncología, Hospitalet, Barcelona, Spain

    J. Saldaña

  5. Medical Oncology Department, H. Universitario Ramón Y Cajal, Madrid, Spain

    C. Guillén-Ponce

  6. Medical Oncology Department, H. Virgen de La Luz, Cuenca, Spain

    M. J. Molina-Garrido

Authors
  1. J. Feliu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Heredia-Soto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Gironés
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Jiménez-Munarriz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Saldaña
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Guillén-Ponce
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. J. Molina-Garrido
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Feliu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

This article does not contain any studies with human participants hence informed consent is not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Feliu, J., Heredia-Soto, V., Gironés, R. et al. Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients. Clin Transl Oncol 22, 457–467 (2020). https://doi.org/10.1007/s12094-019-02167-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-019-02167-y

Keywords

Search

Navigation